Aldeyra Therapeutics Stock Forecast, Price & News

-0.12 (-1.33 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume300,904 shs
Average Volume658,286 shs
Market Capitalization$512.91 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ALDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Aldeyra Therapeutics logo

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.16 out of 5 stars

Medical Sector

380th out of 2,220 stocks

Pharmaceutical Preparations Industry

190th out of 869 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Aldeyra Therapeutics (NASDAQ:ALDX) Frequently Asked Questions

Is Aldeyra Therapeutics a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aldeyra Therapeutics stock.
View analyst ratings for Aldeyra Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Aldeyra Therapeutics?

Wall Street analysts have given Aldeyra Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aldeyra Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Aldeyra Therapeutics?

Aldeyra Therapeutics saw a increase in short interest in June. As of June 30th, there was short interest totaling 6,070,000 shares, an increase of 42.2% from the June 15th total of 4,270,000 shares. Based on an average daily trading volume, of 2,380,000 shares, the short-interest ratio is currently 2.6 days. Currently, 10.8% of the shares of the stock are short sold.
View Aldeyra Therapeutics' Short Interest

When is Aldeyra Therapeutics' next earnings date?

Aldeyra Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Aldeyra Therapeutics

How can I listen to Aldeyra Therapeutics' earnings call?

Aldeyra Therapeutics will be holding an earnings conference call on Thursday, August 5th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) posted its earnings results on Wednesday, May, 5th. The biotechnology company reported ($0.25) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.29) by $0.04.
View Aldeyra Therapeutics' earnings history

How has Aldeyra Therapeutics' stock been impacted by COVID-19?

Aldeyra Therapeutics' stock was trading at $2.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ALDX stock has increased by 219.0% and is now trading at $8.90.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ALDX?

9 equities research analysts have issued twelve-month price targets for Aldeyra Therapeutics' shares. Their forecasts range from $15.00 to $32.00. On average, they expect Aldeyra Therapeutics' share price to reach $25.63 in the next year. This suggests a possible upside of 187.9% from the stock's current price.
View analysts' price targets for Aldeyra Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Aldeyra Therapeutics' key executives?

Aldeyra Therapeutics' management team includes the following people:
  • Todd C. Brady, M.D., Ph.D., Chief Executive Officer and Director (Age 48)
  • Joshua Reed, Chief Financial Officer (Age 47)
  • David McMullin, Chief Commercial Officer (Age 45)
  • James A. Gow, M.D., Senior Vice President of Clinical Development (Age 53)
  • Stephen G. Machatha, Ph.D., Senior Vice President, Technical Operation (Age 43)

Who are some of Aldeyra Therapeutics' key competitors?

What other stocks do shareholders of Aldeyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), KushCo (KSHB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Novan (NOVN), OrganiGram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

What is Aldeyra Therapeutics' stock symbol?

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

Who are Aldeyra Therapeutics' major shareholders?

Aldeyra Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Alliancebernstein L.P. (0.03%). Company insiders that own Aldeyra Therapeutics stock include Ben Bronstein, David Mcmullin, Joshua Reed, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Richard Douglas and Todd C Brady.
View institutional ownership trends for Aldeyra Therapeutics

Which institutional investors are buying Aldeyra Therapeutics stock?

ALDX stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P.. Company insiders that have bought Aldeyra Therapeutics stock in the last two years include Ben Bronstein, David Mcmullin, Joshua Reed, Perceptive Advisors Llc, Richard Douglas, and Todd C Brady.
View insider buying and selling activity for Aldeyra Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aldeyra Therapeutics' stock price today?

One share of ALDX stock can currently be purchased for approximately $8.90.

How much money does Aldeyra Therapeutics make?

Aldeyra Therapeutics has a market capitalization of $512.91 million. The biotechnology company earns $-37,550,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis.

How many employees does Aldeyra Therapeutics have?

Aldeyra Therapeutics employs 15 workers across the globe.

What is Aldeyra Therapeutics' official website?

The official website for Aldeyra Therapeutics is

Where are Aldeyra Therapeutics' headquarters?

Aldeyra Therapeutics is headquartered at 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421.

How can I contact Aldeyra Therapeutics?

Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-761-4904 or via email at [email protected]

This page was last updated on 8/1/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.